Cargando…
Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States
BACKGROUND: Chronic hypersensitivity pneumonitis (CHP) is an interstitial lung disease (ILD) caused by long term exposure to an offending antigen. Antigen avoidance is associated with improved outcomes. We are unable to identify the antigen source in approximately half of patients. When an antigen i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353836/ https://www.ncbi.nlm.nih.gov/pubmed/34376172 http://dx.doi.org/10.1186/s12931-021-01817-6 |
_version_ | 1783736485340512256 |
---|---|
author | Aronson, Kerri I. O’Beirne, Ronan Martinez, Fernando J. Safford, Monika M. |
author_facet | Aronson, Kerri I. O’Beirne, Ronan Martinez, Fernando J. Safford, Monika M. |
author_sort | Aronson, Kerri I. |
collection | PubMed |
description | BACKGROUND: Chronic hypersensitivity pneumonitis (CHP) is an interstitial lung disease (ILD) caused by long term exposure to an offending antigen. Antigen avoidance is associated with improved outcomes. We are unable to identify the antigen source in approximately half of patients. When an antigen is successfully identified, patients have difficulty with avoidance. METHODS: We conducted three structured group discussions with US based ILD specialists utilizing the nominal group technique (NGT). Participants listed barriers to antigen detection and avoidance in CHP. Each participant ranked what they perceived to be the top three barriers in the list in terms of importance. The master list of barriers was consolidated across the three groups into themes that were prioritized based on receiving the highest rankings by participants. RESULTS: Twenty-five physicians participated; 56% had experience caring for CHP patients for ≥ 16 years. Sixty barriers to antigen detection were categorized into seven themes of which the top three were: 1. unclear significance of identified exposures; 2. gaps in clinical knowledge and testing capabilities; 3. there are many unknown and undiscovered antigens. Twenty-eight barriers to antigen avoidance were categorized into five themes of which the top three were: 1. patient limitations, financial barriers and lack of resources; 2. individual patient beliefs, emotions and attachments to the antigen source; and 3. gaps in clinical knowledge and testing capabilities. CONCLUSIONS: This study uncovered challenges at the individual patient, organizational, and societal levels and ranked them in terms of level of importance. These findings provide information to guide development and validation of multidisciplinary support and interventions geared towards antigen identification and avoidance in CHP. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01817-6. |
format | Online Article Text |
id | pubmed-8353836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83538362021-08-11 Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States Aronson, Kerri I. O’Beirne, Ronan Martinez, Fernando J. Safford, Monika M. Respir Res Research BACKGROUND: Chronic hypersensitivity pneumonitis (CHP) is an interstitial lung disease (ILD) caused by long term exposure to an offending antigen. Antigen avoidance is associated with improved outcomes. We are unable to identify the antigen source in approximately half of patients. When an antigen is successfully identified, patients have difficulty with avoidance. METHODS: We conducted three structured group discussions with US based ILD specialists utilizing the nominal group technique (NGT). Participants listed barriers to antigen detection and avoidance in CHP. Each participant ranked what they perceived to be the top three barriers in the list in terms of importance. The master list of barriers was consolidated across the three groups into themes that were prioritized based on receiving the highest rankings by participants. RESULTS: Twenty-five physicians participated; 56% had experience caring for CHP patients for ≥ 16 years. Sixty barriers to antigen detection were categorized into seven themes of which the top three were: 1. unclear significance of identified exposures; 2. gaps in clinical knowledge and testing capabilities; 3. there are many unknown and undiscovered antigens. Twenty-eight barriers to antigen avoidance were categorized into five themes of which the top three were: 1. patient limitations, financial barriers and lack of resources; 2. individual patient beliefs, emotions and attachments to the antigen source; and 3. gaps in clinical knowledge and testing capabilities. CONCLUSIONS: This study uncovered challenges at the individual patient, organizational, and societal levels and ranked them in terms of level of importance. These findings provide information to guide development and validation of multidisciplinary support and interventions geared towards antigen identification and avoidance in CHP. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01817-6. BioMed Central 2021-08-10 2021 /pmc/articles/PMC8353836/ /pubmed/34376172 http://dx.doi.org/10.1186/s12931-021-01817-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Aronson, Kerri I. O’Beirne, Ronan Martinez, Fernando J. Safford, Monika M. Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States |
title | Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States |
title_full | Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States |
title_fullStr | Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States |
title_full_unstemmed | Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States |
title_short | Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States |
title_sort | barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the united states |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353836/ https://www.ncbi.nlm.nih.gov/pubmed/34376172 http://dx.doi.org/10.1186/s12931-021-01817-6 |
work_keys_str_mv | AT aronsonkerrii barrierstoantigendetectionandavoidanceinchronichypersensitivitypneumonitisintheunitedstates AT obeirneronan barrierstoantigendetectionandavoidanceinchronichypersensitivitypneumonitisintheunitedstates AT martinezfernandoj barrierstoantigendetectionandavoidanceinchronichypersensitivitypneumonitisintheunitedstates AT saffordmonikam barrierstoantigendetectionandavoidanceinchronichypersensitivitypneumonitisintheunitedstates |